First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: les
- PDF / 809,631 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 114 Downloads / 144 Views
(2020) 9:143
CASE REPORT
Open Access
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens Joseph Fokam1,2,3,4* , Desire Takou1, Ezechiel Ngoufack Jagni Semengue1,5,6, Georges Teto1, Grace Beloumou1, Beatrice Dambaya1, Maria-Mercedes Santoro5, Leonella Mossiang7, Serge Clotaire Billong2,4,8, Fatim Cham9, Samuel Martin Sosso1, Edith Saounde Temgoua8, Aubin Joseph Nanfack1, Sylvie Moudourou1, Nelly Kamgaing1, Rachel Kamgaing1, Joelle Nounouce Ngako Pamen4,10, Mireille Mpoudi Ngole Etame11, Anne-Cecile Z.-K. Bissek2,4,12, Jean-Bosco N. Elat4,8, Emmanuel Eben Moussi1, Vittorio Colizzi1,5,6, Carlo-Federico Perno1,5,13†, Alexis Ndjolo1,3,4†, On behalf of the VIROFORUM
Abstract Background: Sub-Saharan African countries are transitioning to dolutegravir-based regimens, even for patients with extensive previous drug exposure, including first-generation integrase strand-transfer inhibitors (INSTI) such as raltegravir. Such exposure might have implications on cross-resistance to dolutegravir-based antiretroviral therapies (ART). (Continued on next page)
* Correspondence: [email protected]; [email protected] † Carlo-Federico Perno and Alexis Ndjolo contributed equally to this work. 1 Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon 2 Faculty of Health Sciences, University of Buea, Buea, Cameroon Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Fokam et al. Antimicrobial Resistance and Infection Control
(2020) 9:143
Page 2 of 6
(Continued from previous page)
Case presentation: We report a 65 years old Cameroonian, previously exposed to raltegravir, and failing on thirdline treatment with multi-drug resistance to darunavir/r and dolutegravir. Genotypic resistance testing (GRT) and viral tropism were performed during monit
Data Loading...
